Company intelligence / Profile preview

GNI-EPS

Ownership: Private
Development stage: Other

Overview

GNI-EPS (Hubei) Pharmaceutical is a pharmaceutical manufacturing and development company based in China, operating as a joint venture or subsidiary within the GNI Group ecosystem. The company focuses on the production and commercialization of chemical drug substances (APIs) and finished dosage forms, particularly in the areas of connective tissue diseases and inflammatory conditions. It plays a critical role in the GNI Group's vertically integrated strategy by providing manufacturing capabilities for its internal pipeline and external partners. The facility is designed to meet international GMP standards to support both domestic Chinese and global markets.

Therapeutic areas: ImmunologyRheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

EPS HoldingsBeijing Continent Pharmaceutical

Beyond the preview

Go deeper on GNI-EPS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNI-EPS.

Explore the full profile